Abstract: 5-Fluorouracil (5-FU) is a foundational antimetabolite chemotherapeutic agent widely utilized in the treatment of various solid tumors, including colorectal, pancreatic, head and neck, and anal cancers. By acting as a uracil analog, 5-FU primarily exerts its cytotoxic effects through the inhibition of thymidylate synthase and direct incorporation into DNA and RNA, leading to cell death. Despite its proven efficacy, the clinical utility of 5-FU is often hindered by a narrow therapeutic index, rapid systemic metabolism, and severe toxicities such as mucositis and myelosuppression. To overcome these limitations and combat chemoresistance, current research heavily focuses on integrating 5-FU into advanced combination therapies (e.g., FOLFIRINOX, FOLFOX) and novel immunotherapies, such as immune checkpoint inhibitors (e.g., pembrolizumab). Furthermore, emerging insights into pharmacomicrobiomics reveal that the gut microbiome significantly modulates 5-FU's efficacy and toxicity, presenting new avenues for probiotic and prebiotic interventions. Future perspectives also highlight the development of nanoparticle delivery systems and precision medicine approaches based on genetic profiling to optimize 5-FU-based regimens.
1. Introduction
5-Fluorouracil (5-FU) is a widely utilized, cell-cycle specific antimetabolite drug that has served as a cornerstone in oncology for decades [1][2]. It is primarily employed in the treatment of a diverse array of malignancies, including colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), breast, gastric, pancreatic, and anal cancers [2][6][9]. While 5-FU is traditionally administered via intravenous infusion, oral prodrug formulations such as capecitabine and S-1 have been developed to improve patient convenience and bioavailability [1][3][7].
In contemporary oncology, the research direction for 5-FU has shifted significantly toward combination therapy and immunotherapy. Monotherapy is rarely sufficient due to resistance mechanisms and the complex tumor microenvironment. Consequently, 5-FU is now frequently integrated into multi-agent chemotherapeutic backbones and combined with targeted biological agents and immune checkpoint inhibitors to maximize clinical outcomes and overcome therapeutic resistance [6][8].
2. Pharmacological Activity
5-FU targets the S phase of the cell cycle, effectively inhibiting tumor cell division and proliferation [1][12]. Its pharmacological activity is most prominently leveraged in combination regimens. For instance, 5-FU is a critical component of FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and 5-FU), a regimen that has demonstrated superior overall survival and progression-free survival in metastatic pancreatic cancer [8][10]. It is also combined with liposomal irinotecan (nal-IRI) and leucovorin for patients with advanced pancreatic ductal adenocarcinoma who have progressed on prior therapies [5]. In the treatment of nonmetastatic squamous cell anal cancer, chemoradiation therapy (CRT) combining 5-FU with mitomycin C or cisplatin remains a highly effective standard of care [9].
In the realm of immunotherapy, 5-FU serves as a vital immunomodulatory backbone. The FDA has approved the combination of pembrolizumab (an anti-PD-1 antibody) with platinum-based chemotherapy and 5-FU as a first-line treatment for patients with recurrent or metastatic HNSCC, demonstrating significantly prolonged overall survival [6]. Furthermore, ongoing clinical trials are actively investigating the combination of 5-FU-based regimens (like mFOLFIRINOX) with various immune checkpoint inhibitors (such as atezolizumab and nivolumab) in neoadjuvant and adjuvant settings for gastrointestinal and pancreatic cancers [1][8].
3. Molecular Mechanism of Action
At the molecular level, 5-FU and its oral prodrug capecitabine act as false, high-affinity substrates for the enzyme thymidylate synthase (TS) [3]. By inhibiting TS, 5-FU blocks the de novo biosynthesis of pyrimidines, leading to a severe depletion of endogenous thymidine. Additionally, the active metabolites of 5-FU are directly incorporated into both RNA and DNA, causing structural damage, disrupting ribonucleotide metabolism, and ultimately triggering apoptosis and cell death [2][3].
Recent studies highlight that the molecular efficacy of 5-FU is bidirectionally influenced by the gut microbiome (pharmacomicrobiomics). Bacterial enzymes, such as uracil phosphoribosyltransferase (UPP), can convert 5-FU into 5-fluorouridine monophosphate (FUMP), thereby enhancing its chemotherapeutic efficacy [2]. Conversely, certain gut bacteria like Fusobacterium nucleatum can promote chemoresistance by upregulating the expression of BIRC3 (an inhibitor of apoptosis protein) in cancer cells [1][2]. Microbial metabolites also play a role; for example, butyrate enhances 5-FU sensitivity by modulating the Akt/ERK and SMAD3 signaling pathways and triggering ROS-mediated mitophagy via the PINK1/Parkin pathway [2].
4. Structure-Activity Relationship (SAR)
5-FU is a structural analog of the naturally occurring pyrimidine base, uracil, with a fluorine atom substituted at the C-5 position [2]. This specific halogen substitution is critical, as it allows the molecule to mimic uracil and bind tightly to thymidylate synthase, but the stable carbon-fluorine bond prevents the necessary methylation step required to produce thymidine.
To overcome the pharmacokinetic limitations of the parent structure, prodrugs have been developed. Capecitabine and S-1 are oral fluoropyrimidines designed to be enzymatically converted into active 5-FU within the body, improving bioavailability and allowing for more convenient administration [1][3][7]. The metabolic degradation of the 5-FU structure is primarily mediated by the enzyme dihydropyrimidine dehydrogenase (DPD), which reduces the pyrimidine ring to form the inactive metabolite dihydrofluorouracil (DHFU) [1][4]. Interestingly, the preTA operon found in certain gut bacteria (such as Escherichia coli) can also metabolize 5-FU into DHFU, which can mitigate gastrointestinal toxicity [2].
5. Current Limitations
Despite its widespread use, 5-FU therapy is constrained by several significant limitations:
Pharmacokinetics: Intravenous 5-FU suffers from a very short half-life (approximately 10–15 minutes for a bolus dose), rapid hepatic metabolism, and poor bioavailability, necessitating continuous infusion strategies or the use of prodrugs [1][4].
Toxicity: 5-FU has a narrow therapeutic index. Approximately 20-30% of patients develop severe, sometimes life-threatening toxicities, including hemorrhagic enteritis, oral and intestinal mucositis, cardiotoxicity, and myelosuppression (e.g., neutropenia) [1][2][3]. These adverse events frequently lead to treatment delays and dose reductions.
Genetic Variability: Inter-individual differences in the DPYD gene (which encodes DPD) and the DPYS gene drastically affect drug clearance. Patients with rare or novel variants in these genes are at a substantially higher risk of experiencing severe fluoropyrimidine-induced toxicity [3].
Chemoresistance: Tumors often develop resistance to 5-FU through the overexpression of thymidylate synthase (TS) or enhanced DNA repair mechanisms. Additionally, the gut microbiome can induce resistance; for example, Bacteroides vulgatus stimulates de novo nucleotide biosynthesis, facilitating tumor DNA repair and protecting cancer cells from 5-FU-induced damage [2].
6. Future Perspectives
The future of 5-FU therapy lies in optimizing its delivery, mitigating its toxicity, and enhancing its efficacy through novel combinations:
Nanomedicine: To address the rapid degradation and systemic toxicity of 5-FU, researchers are developing nanoparticle delivery systems. For instance, pegylated albumin-based nanoparticles functionalized to target specific receptors (like LRP-1) have shown promise in improving 5-FU tumor accumulation and significantly enhancing the efficacy of neoadjuvant radiotherapy in rectal cancer models [4].
Pharmacomicrobiomics and Microbiome Modulation: Understanding the drug-microbiome axis offers a new frontier for personalized medicine. Interventions using probiotics (e.g., Lactobacillus plantarum, Streptococcus thermophilus), prebiotics, and postbiotics (like butyrate) are being actively investigated to sensitize tumors to 5-FU, preserve intestinal barrier integrity, and prevent chemotherapy-induced mucositis [1][2].
Precision Dosing: The clinical implementation of pharmacogenetic testing for DPYD and DPYS variants will become increasingly critical. Pre-emptive screening allows for personalized dose adjustments, maximizing therapeutic efficacy while minimizing the risk of fatal toxicities [3].
Advanced Immunotherapy Combinations: As the treatment paradigm shifts, 5-FU will continue to serve as a foundational agent in combination with next-generation immunotherapies. Ongoing trials are exploring the synergy between 5-FU-based chemoradiation and novel immune checkpoint inhibitors (targeting PD-1, PD-L1, CTLA-4, LAG-3, etc.) and antigen-specific vaccines to elicit robust, long-lasting anti-tumor immune responses [6][8].
